Tumor suppressor designated TS10q23.3

Details Tumor suppressor designated TS10q23.3 Tumor suppressor designated TS10q23.3

2006-10-31

2006-10-31

Canella, Karen A. (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S006120, C435S007100, C436S064000, C436S501000

Reexamination Certificate

active

07129040

ABSTRACT:
A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.

REFERENCES:
patent: 6287854 (2001-09-01), Spurr et al.
patent: WO 97/15686 (1997-05-01), None
patent: WO 98/33907 (1998-08-01), None
GenBank Accession No. U93051.
GenBank Accession No. U92437.
GenBank Accession No. U92436.
GenBank Accession No. U92435.
GenBank Accession No. W30684.
Arch, E.M. et al., “Deletion ofPTENin a Patient with Bannayan-Riley-Ruvalcaba Syndrome Suggests Allelism with Cowden Disease,”Am. J. Med. Genets., 1997; 71:489-93.
Albarosa, R. et al., “Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q,”Am J Hum Genet., 1996 58:1260-67.
Bork, P., “Powers and Pitfalls in Sequence Analysis,”Genome Research, 2000; 10:398-400.
Carter, B.S. et al., “Allelic loss of chromosomes 16q and 10q in human prostate cancer,”Proc. Nat. Acad. Sci. USA, 1990; 87:8751-55.
Fujimoto, M. et al., “Loss of Heterozygosity on Chromosome 10 in Human Glioblastoma Multiforme,”Genomics, 1989; 4:210-14.
Fults, D. et al., “Molecular Cytogenetic Analysis of a t(7;10) in a Human Glioblastoma Cell Line,”Cancer Genet. Cytogenet., 1995; 81:118-24.
Gray, I.C. et al., “Loss of the chromosomal region 10q23-25 in prostate cancer,”Cancer Res., 1995; 55:4800-3.
Guldberg, P. et al., “Disruption of theMMAC1/PTENGene by Deletion or Mutation is a Frequent Event in Malignant Melanoma,”Cancer Res., 1997; 57:3660-63.
Herbst, R.A. et al., “Loss of Heterozygosity for 10q22-10qter in Malignant Melanoma Progression,”Cancer Res., 1994; 54:3111-14.
Ittmann, M., “Allelic loss on chromosome 10 in prostate adenocarcinoma,”Cancer Res., 1996; 56:2143-47.
James, C.D. et al., “Clonal genomic alterations in glioma malignancy stages,”Cancer Res., 1988; 48:5546-51.
Karlbom, A.E. et al., Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10,:Hum. Genet., 1993; 92:169-74.
Kimmelman, A.C. et al., “Loss of Heterozygosity of Chromosome 10p in Human Gliomas,”Genomics, 1996; 34:250-54.
Klein, J., “Self-nonself discrimination, histoincompatability, and the concept of immunology,”Immunogenetics, 1999; 50:116-123.
Lacombe, L. et al., “Microsatellite Instability and Deletion Analysis of Chromosome 10 in Human Prostate Cancer,”Int. J. Cancer(Pred. Oncol.), 1996; 69:110-13.
Li, D-M. et al., “TEP1, Encoded by a candidate Tumor Suppressor Locus, is a Novel Protein Tyrosine Phosphatase Regulated by Transforming Growth Factor ∃1,”Cancer Res., 1997; 57:2124-29.
Li, J. et al., “PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer,”Science, 1997; 275:1943-47.
Liaw, D. et al., “Germline mutations of thePTENgene in Cowden disease, an inherited breast and thyroid cancer syndrome,”Nature Genet., 1997; 16:64-67.
Marsh, D.J. et al., “Germline mutations inPTENare present in Bannayan-Zonana syndrome,”Nature Genet., 1997; 16:333-34.
Matthews & Van Holde,Biochemistry(textbook), 2ndEd., pp. 165-171 (1996).
Matthews, B., “Genetic and Structural Analysis of the Protein Stability Problem,”Perspective in Biochemistry, 1989; 1:6-9.
Murakami, Y.S. et al., “Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10,”Cancer Res., 1996; 56:2157-60.
Nelen, M.R. et al., “Germline mutations in thePTEN/MMAC1gene in patients with Cowden disease,”Human Mol. Genets., 1997; 6:1383-87.
Paul, W.E., ed.,Fundamental Immunology(textbook), 3rdEd., pp. 249-251. (1993).
Wilson et al., “2.2 Mb of contiguous nucleotide sequence from chromosome III ofC. elegans,” Nature, 1994; 368:32-38.
Pershouse, M.A. et al. Abstract 400, “Allelic mapping of a tumor suppressing region on chromosome 10q in human glioblastomas,”Am. J. Human Genets., 57:Suppl. Oct. 1995.
Pershouse, M.A. et al. Abstract 1043, “Functional Localization of Tumor Suppressor Genes on Chromosome 10 in Human Glioblastoma,”Proc. Amer. Assoc. Cancer Res., 1994; 35:174.
Pershouse, M.A. et al., “Analysis of the functional role of chromosome 10 loss in human glioblastomas,”Cancer Res., 1993; 53:5043-50.
Proft et al., “Identification and characterization of hitherto unknownMycoplasmapneumonia proteins,”Molecular Microbiology, 1994; 13(2):337-348.
Rasheed, B.K. et al., “Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25,”Oncogene, 1995; 10:2243-46.
Rhei, E. et al., “ Mutation Analysis of the Putative Tumor Suppressor GenePTEN/MMAC1in Primary Breast Carcinomas,”Cancer Res., 1997; 57:3657-59.
Ristori et al., “Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens,”FASEB Journal, 2000; 14:431-438.
Sanchez, Y. et al., “Tumor Suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11,”Proc. Nat. Acad. Sci. USA, 1996; 93:2551-56.
Steck, P.A. et al., “Identification of a candidate tumour suppressor gene,MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers,”Nature Genets., 1997; 15:356-62.
Steck, P.A. et al., “Two Tumor Suppressive Loci on Chromosome 10 Involved in Human Gliobastomas,”Genes, Chromosomes&Cancer, 1995; 12:255-61.
Steck, P.A. et al. Abstract D-605, “Functional Roles of and Localization of Chromosome 10 Deletions in Human Glioblastomas,”J. Cell. Biochem., Suppl. 18A, p. 211 (Jan. 4-23, 1994).
Tashiro, H. et al., “Muttions inPTENare Frequent in Endometrial Carcinoma but Rare in Other Common Gynecological Malignancies,”Cancer Res., 1997; 57:3935-40.
Teng, D. H-F. et al., “MMAC1/PTENmutations in primary tumor specimens and tumor cell lines,”Cancer Res., 1997; 57:5221-25.
Trybus, T.M. et al., “Distinct Areas of Allelic Loss on Chromosomal Regions 10p and 10q in Human Prostate Cancer,”Cancer Res., 1996; 56:2263-67.
Watling, C.J. et al., “Loss of Heterozygosity Analysis of Chromosomes 9, 10 and 17 in Gliomas in Families,”Can. J. Neurol. Sci., 1995; 22:17-21.

Affiliated with

Also associated with

Rating

Tumor suppressor designated TS10q23.3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor suppressor designated TS10q23.3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor suppressor designated TS10q23.3 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3669250